However, pregabalin users had higher use of cyclooxygenase-2 inhibitors (8.6% vs 5.0%) and duloxetine (10.1% vs 5.2%), had a higher prevalence of diabetic neuropathy (15.7% vs 11.2%) and fibromyalgia (20.5% vs 13.5%), and included a lower proportion of White patients (75.1% vs 80.3%) (eTable 5 in Supplement 1). Here, PTGS2 is linked to fibromyalgia.